We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 29.82 | 29.82 | 29.82 | 0.00 | 01:00:00 |
From May 2019 to May 2024
By Cristina Roca
Roche Holding AG (RO.EB) has extended the offering period for its planned acquisition of Philadelphia-based biotechnology company Spark Therapeutics Inc. (ONCE), it said Monday.
The offering period has been extended to July 31, from a previous deadline of June 14, as a result of a request for additional information from the U.S. Federal Trade Commission, or FCA, under the Hart-Scott-Rodino Antitrust Improvements Act. The FCA is reviewing the acquisition of Spark by the Swiss pharmaceuticals company.
The offer period has been extended multiple times since Roche announced in February that it would buy Spark.
Roche said the U.K. Competition and Markets Authority has opened an investigation in order to obtain further information in relation to Roche's proposed acquisition of Spark.
Write to Cristina Roca at cristina.roca@dowjones.com; @_cristinaroca
(END) Dow Jones Newswires
June 10, 2019 01:37 ET (05:37 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
